Dossier assessment
Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
-
Dossier assessment
Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Press releases
Apixaban in deep vein thrombosis and pulmonary embolism: patients with high BMI benefit considerably
Additional information
IQWiG health information
Deep vein thrombosis (DVT) occurs when a blood clot forms in a vein. This can cause symptoms like tenderness, skin redness, swelling in the lower leg, or warmth in the affected area. But DVT often causes no symptoms at all.
Federal Joint Committee (G-BA)
2015-02-19 A G-BA decision was published.
Project details
- Project no.
- A14-28
- Commission
- Commission awarded on 25.08.2014 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed